PME-1 suppresses anoikis, and is associated with therapy relapse of PTEN-deficient prostate cancers
A. Aakula, A. Isomursu, C. Rupp, A. Erickson, O. Kauko, P. Shah, A. Padzik, Y. R. Pokharel, A. Kaur, S.-P. Li, L. Trottman, P. Taimen, A. Rannikko, J. Lammerding, I. Paatero, , J. Westermarck
This study identifies PME-1 as a biomarker for aggressive PTEN-deficient prostate cancers by showing its role in suppressing anoikis.
bioRxiv · Mar 17, 2022 · PreprintCancer Biology